5.52
-0.0172(-0.31%)
Currency In USD
| Previous Close | 5.54 |
| Open | 5.5 |
| Day High | 5.59 |
| Day Low | 5.44 |
| 52-Week High | 7.63 |
| 52-Week Low | 3.38 |
| Volume | 3.24M |
| Average Volume | 3.96M |
| Market Cap | 1.69B |
| PE | 50.21 |
| EPS | 0.11 |
| Moving Average 50 Days | 3.99 |
| Moving Average 200 Days | 5.02 |
| Change | -0.02 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $271.39 as of September 08, 2025 at a share price of $5.523. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $3,388.22 as of September 08, 2025 at a share price of $5.523.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
GlobeNewswire Inc.
Aug 27, 2025 12:05 PM GMT
Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertensionDANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that United
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
GlobeNewswire Inc.
Aug 25, 2025 11:30 AM GMT
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
GlobeNewswire Inc.
Aug 06, 2025 11:10 AM GMT
Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporati